Jubilant Pharmova’s step down arm signs, issues put option offer to Pierre Fabre Laboratories

19 Aug 2024 Evaluate

Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Biosys’ (JBL) subsidiary -- Jubilant Biosys Innovative Research Services Pte, Singapore has signed and issued a ‘put option offer’ to Pierre Fabre Laboratories, which sets forth an offer to acquire 80% equity capital (around Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France.

The R&D centre has a capability of conducting discovery and preclinical development activities in immune-oncology. The facilities include research labs & office space including parking area surrounded by green field.

Pierre Fabre Laboratories may invest 20% equity capital (around Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company. In addition to that, Pierre Fabre Laboratories may also hire services from Jubilant Biosys aggregating to Euro 7 million for first 4 years post-closing date.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1076.50 7.30 (0.68%)
05-Dec-2025 15:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1803.50
Dr. Reddys Lab 1274.50
Cipla 1520.00
Zydus Lifesciences 930.75
Lupin 2098.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×